Clinical Trial Detail

NCT ID NCT03123588
Title Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

essential thrombocythemia

Therapies

Ruxolitinib

Anagrelide

Age Groups: adult senior

No variant requirements are available.